Research programme: attention deficit hyperactivity disorder therapeutics - Egalet

Drug Profile

Research programme: attention deficit hyperactivity disorder therapeutics - Egalet

Alternative Names: EG-P119

Latest Information Update: 12 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Egalet
  • Class
  • Mechanism of Action Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Attention-deficit hyperactivity disorder

Most Recent Events

  • 05 Jun 2017 Egalet has patent protection for Guardian Technology in USA
  • 23 Mar 2017 Egalet has patent protection for Guardian™ Technology in Europe, Australia and Canada
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in Denmark (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top